Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Revenue (2016 - 2025)

BioCorRx's Revenue history spans 15 years, with the latest figure at $635225.0 for Q3 2025.

  • For Q3 2025, Revenue changed N/A year-over-year to $635225.0; the TTM value through Sep 2025 reached $948362.0, up 3464.87%, while the annual FY2024 figure was $7665.0, 91.4% down from the prior year.
  • Revenue for Q3 2025 was $635225.0 at BioCorRx, up from $178238.0 in the prior quarter.
  • Across five years, Revenue topped out at $635225.0 in Q3 2025 and bottomed at $3620.0 in Q1 2024.
  • The 5-year median for Revenue is $18938.0 (2023), against an average of $76900.0.
  • The largest annual shift saw Revenue plummeted 91.05% in 2024 before it skyrocketed 4306.38% in 2025.
  • A 5-year view of Revenue shows it stood at $13613.0 in 2021, then soared by 508.83% to $82880.0 in 2022, then crashed by 77.15% to $18938.0 in 2023, then crashed by 78.64% to $4045.0 in 2024, then surged by 15603.96% to $635225.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Revenue are $635225.0 (Q3 2025), $178238.0 (Q2 2025), and $134899.0 (Q1 2025).